针对严重急性呼吸综合征冠状病毒、尼帕病毒和亨德拉病毒的强效人源单克隆抗体。
Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses.
作者信息
Prabakaran Ponraj, Zhu Zhongyu, Xiao Xiaodong, Biragyn Arya, Dimitrov Antony S, Broder Christopher C, Dimitrov Dimiter S
机构信息
Protein Interactions, CCRNP, NCI-Frederick, NIH, Building 469, 150B, P.O. Box B, Miller Drive, Frederick, MD 21702 1201, USA.
出版信息
Expert Opin Biol Ther. 2009 Mar;9(3):355-68. doi: 10.1517/14712590902763755.
Abstract
BACKGROUND
Recently, several potently neutralizing fully human monoclonal antibodies (hmAbs) targeting the severe acute respiratory syndrome-associated coronavirus (SARS CoV) S glycoprotein, and the G glycoprotein of the paramyxoviruses Hendra virus (HeV) and Nipah virus (NiV) have been discovered [corrected].
OBJECTIVE
To examine, compare and contrast the functional characteristics of hmAbs with the potential for prophylaxis and treatment of diseases caused by SARS CoV, HeV and NiV.
METHODS
A review of relevant literature.
RESULTS/CONCLUSIONS: Structural, functional and biochemical analyses [corrected] have provided insights into the molecular mechanisms of receptor recognition and antibody neutralization, and suggested that these antibodies alone or in combination could fight the viruses' heterogeneity and mutability, which is a major problem in the development of effective therapeutic agents against viruses, including therapeutic antibodies.
摘要
背景
最近，已经发现了几种针对严重急性呼吸综合征相关冠状病毒（SARS-CoV）S糖蛋白以及副粘病毒亨德拉病毒（HeV）和尼帕病毒（NiV）G糖蛋白的强效中和全人单克隆抗体（hmAb）[已修正]。
目的
研究、比较和对比具有预防和治疗由SARS-CoV、HeV和NiV引起疾病潜力的hmAb的功能特性。
方法
对相关文献进行综述。
结果/结论：结构、功能和生化分析[已修正]为受体识别和抗体中和的分子机制提供了见解，并表明这些抗体单独或联合使用可以对抗病毒的异质性和变异性，这是开发包括治疗性抗体在内的有效抗病毒治疗药物的一个主要问题。
相似文献
1
Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses.针对严重急性呼吸综合征冠状病毒、尼帕病毒和亨德拉病毒的强效人源单克隆抗体。
Expert Opin Biol Ther. 2009 Mar;9(3):355-68. doi: 10.1517/14712590902763755.
2
Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies.人源单克隆抗体对亨德拉病毒和尼帕病毒的强效中和作用。
J Virol. 2006 Jan;80(2):891-9. doi: 10.1128/JVI.80.2.891-899.2006.
3
Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1.人源单克隆抗体作为针对新兴病毒和 HIV-1 的候选治疗药物。
Virol Sin. 2013 Apr;28(2):71-80. doi: 10.1007/s12250-013-3313-x. Epub 2013 Apr 11.
4
Potent Henipavirus Neutralization by Antibodies Recognizing Diverse Sites on Hendra and Nipah Virus Receptor Binding Protein.强效亨德拉尼帕病毒中和抗体通过识别亨德拉和尼帕病毒受体结合蛋白上不同位点。
Cell. 2020 Dec 10;183(6):1536-1550.e17. doi: 10.1016/j.cell.2020.11.023.
5
Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody.一种人源单克隆抗体对尼帕病毒和亨德拉病毒具有极强的交叉反应性中和作用。
J Infect Dis. 2008 Mar 15;197(6):846-53. doi: 10.1086/528801.
6
Broadly neutralizing antibody cocktails targeting Nipah virus and Hendra virus fusion glycoproteins.针对尼帕病毒和亨德拉病毒融合糖蛋白的广谱中和抗体鸡尾酒。
Nat Struct Mol Biol. 2021 May;28(5):426-434. doi: 10.1038/s41594-021-00584-8. Epub 2021 Apr 29.
7
Construction of the safe neutralizing assay system using pseudotyped Nipah virus and G protein-specific monoclonal antibody.利用假型尼帕病毒和 G 蛋白特异性单克隆抗体构建安全中和测定系统。
Biochem Biophys Res Commun. 2019 Jun 11;513(4):781-786. doi: 10.1016/j.bbrc.2019.03.212. Epub 2019 Apr 15.
8
Vaccines to Emerging Viruses: Nipah and Hendra.新兴病毒疫苗：尼帕病毒和亨德拉病毒。
Annu Rev Virol. 2020 Sep 29;7(1):447-473. doi: 10.1146/annurev-virology-021920-113833.
9
Acute Hendra virus infection: Analysis of the pathogenesis and passive antibody protection in the hamster model.急性亨德拉病毒感染：仓鼠模型中的发病机制及被动抗体保护分析
Virology. 2009 May 10;387(2):459-65. doi: 10.1016/j.virol.2009.03.001. Epub 2009 Mar 28.
10
Identification of a broad-spectrum antiviral small molecule against severe acute respiratory syndrome coronavirus and Ebola, Hendra, and Nipah viruses by using a novel high-throughput screening assay.采用新型高通量筛选检测法鉴定广谱抗严重急性呼吸综合征冠状病毒和埃博拉、亨德拉及尼帕病毒的小分子抗病毒药物。
J Virol. 2014 Apr;88(8):4353-65. doi: 10.1128/JVI.03050-13. Epub 2014 Feb 5.
引用本文的文献
1
Nipah virus: pathogenesis, genome, diagnosis, and treatment.尼帕病毒：发病机制、基因组、诊断与治疗
Appl Microbiol Biotechnol. 2025 Jul 1;109(1):158. doi: 10.1007/s00253-025-13474-6.
2
Mapping immunological and host receptor binding determinants of SARS-CoV spike protein utilizing the Qubevirus platform.利用 Qubevirus 平台绘制 SARS-CoV 刺突蛋白的免疫学和宿主受体结合决定因素图谱。
J Biol Chem. 2023 Dec;299(12):105460. doi: 10.1016/j.jbc.2023.105460. Epub 2023 Nov 15.
3
In silico designing of an epitope-based peptide vaccine cocktail against Nipah virus: an Indian population-based epidemiological study.针对尼帕病毒的基于表位的肽疫苗鸡尾酒的计算机辅助设计：一项基于印度人群的流行病学研究。
Arch Microbiol. 2023 Nov 13;205(12):380. doi: 10.1007/s00203-023-03717-3.
4
Computational design of nanomolar-binding antibodies specific to multiple SARS-CoV-2 variants by engineering a specificity switch of antibody 80R using RosettaAntibodyDesign (RAbD) results in potential generalizable therapeutic antibodies for novel SARS-CoV-2 virus.通过使用Rosetta抗体设计（RAbD）工程改造抗体80R的特异性开关，针对多种SARS-CoV-2变体设计出具有纳摩尔结合力的抗体，从而为新型SARS-CoV-2病毒开发出具有潜在广泛适用性的治疗性抗体。
Heliyon. 2023 Apr;9(4):e15032. doi: 10.1016/j.heliyon.2023.e15032. Epub 2023 Apr 3.
5
Phase 1 study of safety, pharmacokinetics, and antiviral activity of SARS-CoV-2 neutralizing monoclonal antibody ABBV-47D11 in patients with COVID-19.一项评估 COVID-19 患者中 SARS-CoV-2 中和单克隆抗体 ABBV-47D11 的安全性、药代动力学和抗病毒活性的 1 期研究。
Pharmacol Res Perspect. 2023 Feb;11(1):e01036. doi: 10.1002/prp2.1036.
6
Recent advances in passive immunotherapies for COVID-19: The Evidence-Based approaches and clinical trials.新型冠状病毒肺炎被动免疫治疗的最新进展：基于证据的方法和临床试验。
Int Immunopharmacol. 2022 Aug;109:108786. doi: 10.1016/j.intimp.2022.108786. Epub 2022 Apr 21.
7
Effectiveness and Safety of Regdanvimab in Patients With Mild-To-Moderate COVID-19: A Retrospective Cohort Study.Regdanvimab 治疗轻至中度 COVID-19 患者的有效性和安全性：一项回顾性队列研究。
J Korean Med Sci. 2022 Apr 4;37(13):e102. doi: 10.3346/jkms.2022.37.e102.
8
Identification and Development of Therapeutics for COVID-19.新型冠状病毒肺炎治疗方法的识别与开发
mSystems. 2021 Dec 21;6(6):e0023321. doi: 10.1128/mSystems.00233-21. Epub 2021 Nov 2.
9
Bifunctional molecules targeting SARS-CoV-2 spike and the polymeric Ig receptor display neutralization activity and mucosal enrichment.双功能分子靶向 SARS-CoV-2 刺突蛋白和多聚免疫球蛋白受体，显示出中和活性和黏膜富集。
MAbs. 2021 Jan-Dec;13(1):1987180. doi: 10.1080/19420862.2021.1987180.
10
A comprehensive review of COVID-19 biology, diagnostics, therapeutics, and disease impacting the central nervous system.全面综述 COVID-19 的生物学、诊断学、治疗学，以及对中枢神经系统产生影响的疾病。
J Neurovirol. 2021 Oct;27(5):667-690. doi: 10.1007/s13365-021-00998-6. Epub 2021 Sep 28.
本文引用的文献
1
Host cell recognition by the henipaviruses: crystal structures of the Nipah G attachment glycoprotein and its complex with ephrin-B3.亨尼帕病毒对宿主细胞的识别：尼帕病毒G附着糖蛋白及其与ephrin-B3复合物的晶体结构
Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):9953-8. doi: 10.1073/pnas.0804797105. Epub 2008 Jul 16.
2
Structural basis of Nipah and Hendra virus attachment to their cell-surface receptor ephrin-B2.尼帕病毒和亨德拉病毒附着于其细胞表面受体埃菲林-B2的结构基础。
Nat Struct Mol Biol. 2008 Jun;15(6):567-72. doi: 10.1038/nsmb.1435. Epub 2008 May 18.
3
Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody.一种人源单克隆抗体对尼帕病毒和亨德拉病毒具有极强的交叉反应性中和作用。
J Infect Dis. 2008 Mar 15;197(6):846-53. doi: 10.1086/528801.
4
Antiviral immunotherapy: a review of current status.抗病毒免疫疗法：现状综述。
BioDrugs. 1998 Jun;9(6):487-507. doi: 10.2165/00063030-199809060-00006.
5
Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies.人源单克隆抗体对严重急性呼吸综合征冠状病毒分离株的强效交叉反应中和作用。
Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12123-8. doi: 10.1073/pnas.0701000104. Epub 2007 Jul 9.
6
Structural definition of a conserved neutralization epitope on HIV-1 gp120.HIV-1 gp120上保守中和表位的结构定义
Nature. 2007 Feb 15;445(7129):732-7. doi: 10.1038/nature05580.
7
Neutralization assays for differential henipavirus serology using Bio-Plex protein array systems.使用Bio-Plex蛋白芯片系统进行鉴别亨尼帕病毒血清学的中和试验。
J Virol Methods. 2007 Jun;142(1-2):29-40. doi: 10.1016/j.jviromet.2007.01.003. Epub 2007 Feb 9.
8
Structural basis of neutralization by a human anti-severe acute respiratory syndrome spike protein antibody, 80R.人源抗严重急性呼吸综合征刺突蛋白抗体80R的中和作用结构基础
J Biol Chem. 2006 Nov 10;281(45):34610-6. doi: 10.1074/jbc.M603275200. Epub 2006 Sep 5.
9
Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants.抗SARS冠状病毒的人源单克隆抗体组合：协同作用及对逃逸突变体的覆盖范围
PLoS Med. 2006 Jul;3(7):e237. doi: 10.1371/journal.pmed.0030237.
10
Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody.与中和抗体复合的严重急性呼吸综合征冠状病毒受体结合结构域的结构
J Biol Chem. 2006 Jun 9;281(23):15829-36. doi: 10.1074/jbc.M600697200. Epub 2006 Apr 5.
Zotero 插件